Aroa Biosurgery (ARX) Q1 2025 earnings summary

Executive summary

• Cash receipts for the quarter were NZ$17.8 million, with a net operating cash outflow of NZ$3.6 million, reflecting post-year payments and clinical trial costs; company expects to be operating cash flow positive in H2 FY25.

• Cash balance at quarter-end was NZ$23.9 million, with no debt and ongoing investments in manufacturing expansion.

• Strong US commercial momentum, with Myriad active accounts up 11% quarter-on-quarter to 242 and a 17.5% increase in average sales by newer representatives.

• Regulatory milestones achieved in Taiwan, Switzerland, Chile, and South Africa, expanding global reach.

• Completion of Symphony RCT enrollment (120 patients) and expansion of the MASTRR study to 15 sites and up to 800 patients.

Financial highlights

• Net cash outflow from investing activities was NZ$1.6 million, mainly for plant equipment and manufacturing capacity expansion.

• FY25 revenue guidance maintained at NZ$80–87 million and EBITDA profit guidance at NZ$2–6 million, assuming stable FX and TELA Bio performance.

• Product gross margin improved to 85% in FY24 and is expected to exceed 85% in FY25.

• R&D investment maintained at 10% of sales, projected to decline as a percentage of sales.

• Aggregate payments to non-executive directors totaled NZ$164,000 for the quarter.

Outlook and guidance

• FY25 revenue guidance is NZ$80–87 million, representing 21–32% constant currency growth on FY24.

• Normalised EBITDA guidance for FY25 is NZ$2–6 million, a turnaround from FY24's negative NZ$3 million.

• Company expects to be operating cash flow positive in H2 FY25.

• Guidance assumes TELA Bio delivers on its US$74.5–76.5 million revenue target for CY24.

• Operating leverage expected to increase as sales team matures and productivity rises.